Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 801 - 825 of 14983 in total

Levallorphan

An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia,...
Approved

Phenprocoumon

Coumarin derivative that acts as a long-acting oral anticoagulant.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …

Lurbinectedin

Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate...
Approved
Investigational
Matched Description: … including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and ... [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed ... in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Idarubicin

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Approved
Matched Description: … The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …

Cisapride

In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …

Teriparatide

Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in...
Approved
Investigational
Matched Description: … Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. ... [A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595] ... [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Siponimod

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Iupac: … cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid …
Matched Description: … , disrupting communication between the brain and other parts of the body. ... It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ozenoxacin

To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Iupac: … cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Matched Description: … has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. ... Despite being a common and highly contagious bacerial skin infection that affects millions of children …

Besifloxacin

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Approved
Matched Iupac: … 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …

Amisulpride

Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in...
Approved
Investigational
Matched Description: … D2 and D3 receptors. ... , and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major ... Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine …
Matched Categories: … Benzamides and benzamide derivatives …

Albumin human

Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood . It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Albumin represents approximately...
Approved
Matched Description: … ) and pharmaceuticals (including barbiturates). ... both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101]. ... Each domain comprises two separate sub-domains (A and B) [A40060]. …
Matched Categories: … Blood and Related Products ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Blood Substitutes and Perfusion Solutions ... Blood Substitutes and Plasma Protein Fractions …

Clotiazepam

Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.
Approved
Illicit
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …

Ciltacabtagene autoleucel

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational
Matched Description: … It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[L40749] and is ... [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant ... asymptomatic, while others may experience a range of symptoms including bone pain, hematologic abnormalities, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Nadofaragene firadenovec

Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without...
Approved
Investigational
Matched Description: … [L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. ... firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and …
Matched Categories: … Cellular and Gene Therapy ... Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Hexetidine

A bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene.
Approved
Investigational
Matched Description: … A bactericidal and fungicidal antiseptic. ... It is used as a 0.1% mouthwash for local infections and oral hygiene. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …

Etrasimod

Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes. Therefore, S1P receptor modulators like etrasimod...
Approved
Matched Iupac: … 3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid …
Matched Description: … 26% remission rate observed in UC 52 and UC 12 trials respectively. ... receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and ... obtained from Pfizer’s Elevate UC Phase III registrational program, consisting of the Elevate UC 52 and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Apixaban

Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28,...
Approved
Matched Description: … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa ... , as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic …
Matched Categories: … Blood and Blood Forming Organs …

Dabigatran

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Approved
Investigational
Matched Iupac: … carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid …

Glofitamab

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Description: … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting ... antigens found on B- and T-cells, respectively. ... Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Glymidine

Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta...
Approved
Investigational
Matched Description: … Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and ... appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and ... ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Hexamidine

Approved
Experimental
Matched Categories: … Biguanides and Amidines ... Antiseptics and Disinfectants ... Ophthalmological and Otological Preparations …

Lifileucel

Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational
Matched Description: … suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Medrogestone

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Terizidone

Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
Approved
Investigational
Matched Description: … in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and …

Tremelimumab

Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 801 - 825 of 14983 in total